Podcasts about stage iiia

Chelsee Wilson was diagnosed at 29 with Stage IIIa, Triple Positive breast cancer. She is now 5+ years out from diagnosis. Chelsee lives in Oklahoma with her husband and loves baking, crocheting, reading and writing. In this episode she reads her essay “The Power of No” from the 2022 “Identity & Aftermath” issue of Wildfire Magazine. Her story is about one woman's quest to break cycles. April and Chelsee will discuss protecting mental health, mental health outlets, quality of life and the biggest challenges of long-term survivorship. They will also discuss what books they are reading.More about Chelsee: https://www.instagram.com/chelseelior/This episode was brought to you in collaboration with After Breast Cancer Diagnosis (ABCD):https://abcdbreastcancersupport.org/https://www.instagram.com/abcdafterbreastcancerdiagnosis/https://www.facebook.com/ABCDAfterBreastCancerDiagnosis/?ref=tshttps://www.youtube.com/channel/UCY4VHSTPyU1IYyT1fNesmAgPurchase the “Identity & Aftermath” issue of Wildfire Magazine: https://www.wildfirecommunity.org/shop/p/digital-mbc22Buy the Wildfire book Igniting the Fire Within: Stories of Healing, Hope & Humor, Inside Today's Young Breast Cancer Community: https://www.amazon.com/dp/B0BJVJ629F?ref_=pe_3052080_397514860Get the free Wildfire “Hot Flashes” email newsletter: https://www.wildfirecommunity.org/newsletter?rq=newsletterLearn about Wildfire writing workshops: https://www.wildfirecommunity.org/workshopsShop Wildfire merch & more: https://www.wildfirecommunity.org/shop*Free* Get Wildfire and The Burn freebies here: https://www.wildfirecommunity.org/freeMore about Wildfire Magazine: https://www.wildfirecommunity.orghttps://www.instagram.com/wildfire_bc_magazine/https://www.facebook.com/wildfirecommunityInformation on submitting your story for consideration to be published in Wildfire Magazine: https://www.wildfirecommunity.org/submissions

Featuring perspectives from Dr Antonio González-Martín, including the following topics: Introduction: Treatment-Related Second Cancers (0:00) Case: A woman in her mid 40s (gBRCA) who presents with ascites and is diagnosed with high-grade serous ovarian cancer (HGSOC) with extensive peritoneal disease — Lyndsay J Willmott, MD (12:37) Case: A woman in her early 40s (gBRCA1) with HGSOC who experienced cardiac arrest due to anaphylaxis during paclitaxel infusion as part of a neoadjuvant paclitaxel/carboplatin/bevacizumab regimen — Kellie E Schneider, MD (30:33) Case: A woman in her late 50s (gBRCA1) with HGSOC and pelvic node recurrence after perioperative paclitaxel/carboplatin and optimal interval debulking surgery — Karim ElSahwi, MD (39:45) Case: A woman in her late 50s (gBRCA1) with Stage IIIA ovarian cancer and elevated creatinine due to donor nephrectomy — Paul DiSilvestro, MD (43:05) Case: A woman in her early 60s with recurrent ovarian cancer after a chemotherapy and niraparib maintenance regimen and tumor treating fields with paclitaxel on a clinical trial — Gigi Chen, MD (46:28) Case: A woman in her late 50s with gBRCA1 and PMH of breast cancer and prophylactic bilateral salpingo-oophorectomy who develops recurrent peritoneal cancer and responds for 10 months to olaparib followed by chemotherapy followed by rucaparib and nivolumab on the TAPUR trial — John K Chan, MD (51:52) Journal Club (55:30) CME information and select publications

Featuring perspectives from Prof Georgina Long, including the following topics: Introduction: (0:00) Journal Club with Prof Long – Part 1 (7:56) Case: A man in his mid 70s presents with bilateral painfully inflamed red ears and is diagnosed with BRAF V600E-mutated metastatic melanoma — Joanna Metzner-Sadurski, MD (27:19) Case: A man in his early 70s with past medical history of diabetes, hypertension, chronic obstructive pulmonary disease and several skin cancers is diagnosed with BRAF wild-type Stage IIIA melanoma — Helen H Moon, MD (32:52) Case: A man in his late 50s with past medical history of Stage III melanoma and multiple metastatic recurrences responds to single-agent pembrolizumab — Warren S Brenner, MD (43:02) Case: A man in his mid 70s develops metastatic recurrence of melanoma after relatlimab/nivolumab on clinical trial and pembrolizumab therapy for Stage III BRAF V600K-mutated melanoma — Priya Rudolph, MD (50:48) Case: A woman in her mid 30s with a personal and family history of melanoma develops multiple axillary nodes with BRAF-mutated melanoma without a primary lesion — Dr Moon (58:18) CME information and select publications

Adversity – a state or instance of serious or continued difficulty or misfortuneAll men face adversity at various points in their lives. When it strikes, we are faced with a choice. We can either choose to fight or we can choose to give up. Nobody remembers the man who gives up.There are few examples of adversity more harrowing than a cancer diagnosis. Staring down the very real possibility of your own mortality can bring even the strongest of men to their knees. In those moments, it's paramount that we stand up and fight relentlessly.In this episode of Untaming Masculinity, Dan and Brad are joined by their friend Andy Musser. Andy is a landscaper and hardscaper by trade, an avid outdoorsman, a husband, and a father. In this remarkable conversation, Andy shares his experience of finding out he had cancer only weeks after finding out he was going to be a father, just as everything in life was falling into place.He talks about how he was initially misdiagnosed with Stage IV colon cancer, being told he only had a couple of years to live, and how those initial dark days led him to turn to God and choose hope.After that initial misdiagnosis, Andy was diagnosed with Stage IIIA colon cancer and approached his treatment and inevitable recovery with tenacity and relentlessness. He chose to study his enemy, fight aggressively, and never concede. That tenacity eventually led to his ultimate victory: a clean bill of health and being cancer-free.Andy admits that he is grateful for cancer. Not because of the illness itself, but the lessons it taught him that he has now extended to all areas of his life. This is a story of determination and resiliency and one of our most powerful conversations yet.Follow AndyInstagramSubscribe and ShareSubscribe to our YouTube channelConnect with Dan on Instagram and TwitterConnect with Brad on Instagram and TwitterFollow Untaming Masculinity on Instagram and TwitterJoin the Untaming Masculinity Facebook GroupPlease leave us a rating and review

Advocate Ricki Fairley was diagnosed at 55 with Stage IIIa, Triple Negative breast cancer. She is the CEO and co-founder of TOUCH, The Black Breast Cancer Alliance. She is a marketing veteran, and serves on the board of the Triple Negative Breast Cancer Foundation and the Center for Healthcare Innovation. In this episode Ricki reads her essay “When We Tri(al): A Movement to Advance Breast Cancer Science for Black Women'' from Wildfire Magazine's 2022 “Body” issue. April and Ricki will discuss how Ricki focused on black breast cancer to form TOUCH, folding your own story into advocacy, and advice on seeking second opinions. They will also discuss using writing to think through thoughts and form opinions. This episode contains explicit language.More about TOUCH, The Black Breast Cancer Alliance: https://touchbbca.org/More about When We Tri(al): https://www.whenwetrial.org/More on The Wisdom Study: https://www.thewisdomstudy.org/More on Triple Negative Breast Cancer Foundation: https://tnbcfoundation.org/Get the free Wildfire email newsletter: https://www.wildfirecommunity.orgLearn about Wildfire writing workshops: https://www.wildfirecommunity.org/workshopsShop Wildfire merch & more: https://www.wildfirecommunity.org/shopSend your voice recording testimonial to editor@wildfirecommunity.org*Free* The Burn Writing Companion: Guided Prompt Journal (Vol. 1): https://www.wildfirecommunity.org/the-burnBuy the Wildfire book “Igniting the Fire Within: Stories of Healing, Hope & Humor, Inside Today's Young Breast Cancer Community”: https://www.amazon.com/dp/B0BJVJ629F?ref_=pe_3052080_397514860

Featuring perspectives from Drs Erika Hamilton, Sara Hurvitz, Ian Krop, Shanu Modi and Sara Tolaney, including the following topics: Optimizing the Management of Localized HER2-Positive Breast Cancer Introduction (0:00) Case: A woman in her mid 60s with pulmonary hypertension and triple-positive, node-positive infiltrating ductal carcinoma (IDC) after neoadjuvant TCHP and clinical complete remission — Susmitha Apuri, MD (4:31) Case: A woman in her early 60s with a 1.7-cm, triple-positive, clinically node-negative IDC — Ranju Gupta, MD (10:05) Dr Tolaney presentation (18:44) Current Considerations in the Treatment of HER2-Positive Metastatic Breast Cancer (mBC) Case: A woman in her early 60s with an 8-cm, ER-negative, PR-positive, HER2-positive IDC and positive nodes bilaterally after neoadjuvant TCHP and bilateral mastectomies with no residual disease — Henna Malik, MD (31:12) Case: A woman in her late 50s with Stage IIIA, ER/PR-negative, HER2-positive, node-positive IDC with residual disease after neoadjuvant TCHP and mastectomy — Laila Agrawal, MD ()35:29 Dr Krop presentation (42:56) Management of HER2-Positive Breast Cancer with CNS Metastases Case: A woman in her early 90s with “mild” dementia and ER/PR-negative, HER2 IHC 1+ IDC with symptomatic chest wall recurrence after neoadjuvant paclitaxel/trastuzumab and lumpectomy — Alan B Astrow, MD (54:54) Case: A woman in her late 40s with a triple-positive multifocal IDC with a gBRCA2 mutation and HER2-negative axillary nodes after neoadjuvant TCHP and bilateral mastectomies with significant response in the breast but 49 positive nodes — Zanetta S Lamar, MD (1:00:01) Dr Hamilton presentation (1:06:51) Recent Appreciation of HER2 Low as a Unique Disease Subset; Future Directions in the Management of HER2-Positive and HER2-Low Breast Cancer Cases: A premenopausal woman in her late 30s with a triple-positive IDC who develops brain metastases while receiving THP; A woman in her late 60s with an ER/PR-negative, HER2-positive IDC who develops brain metastases after first-line THP and second-line T-DM1 — Kelly Yap, MD & Rohit Gosain, MD (1:20:46) Case: A woman in her mid 60s with ER/PR-negative, HER2-positive mBC treated with paclitaxel/trastuzumab, then T-DXd on progression — Joanna Metzner-Sadurski, MD (1:29:40) Dr Modi presentation (1:40:51) Incidence and Management of Adverse Events Associated with HER2-Targeted Therapy Case: A woman in her early 60s with recurrent triple-positive mBC whose disease converts to HER2-negative, PIK3CA-positive at the time of progression — Dhatri Kodali, MD (2:01:10) Dr Hurvitz presentation (2:05:08) CME information and select publications

Featuring perspectives from Dr Paul Richardson, including the following topics: Introduction (0:00) Case: A man in his early 60s with newly diagnosed Stage II standard-risk multiple myeloma — Ranju Gupta, MD (29:31) Case: A woman in her early 70s with Stage IIIA multiple myeloma who receives lenalidomide/bortezomib/dexamethasone → autologous stem cell transplant (ASCT) and discontinues maintenance lenalidomide after 3 years — Erik Rupard, MD (34:16) Case: A woman in her early 70s with relapsed myeloma after tandem ASCT who receives cyclophosphamide/bortezomib/dexamethasone, achieves minimum residual disease negativity and is now on maintenance ixazomib — Zanetta S Lamar, MD (39:01) Case: A woman in her early 70s with triple-class refractory t(11;14) multiple myeloma — Hans Lee, MD (43:47) Case: A man in his mid 60s with high-risk relapsed multiple myeloma after carfilzomib/lenalidomide/dexamethasone (KRd) induction, ASCT, maintenance KRd and 2 additional lines of therapy — Muzaffar H Qazilbash, MD (46:05) Faculty Survey (52:29) Journal Club with Dr Richardson (60:57) CME information and select publications

Proceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in lung cancer. Featuring perspectives from Drs Lecia Sequist and David Spigel, including the following topics: Introduction Case: A woman in her early 70s with microsatellite stable metastatic adenocarcinoma of the lung and a HER2 mutation, PD-L1 TPS 0% — Dr Zafar Case: A man in his mid-80s with localized adenocarcinoma of the lung and an EGFR exon 19 deletion — Dr Gandhi Case: A woman in her late 70s with metastatic adenocarcinoma of the lung, somatic BRCA2 and KRAS G12C mutations and high tumor mutation burden (TMB) — Kapisthalam (KS) Kumar, MD Targeted Therapy for Lung Cancer Chalk Talk — Dr Spigel Case: A man in his mid-60s with Stage IIIA (8-cm, node-negative) adenocarcinoma of the lung — Shachar Peles, MD Case: A man in his mid-50s with Stage IIIA adenocarcinoma of the lung — Dr Choksi Case: A woman in her mid-60s with metastatic adenocarcinoma of the lung, PD-L1 56% — Dr Gandhi First-Line Treatment of PD-L1-Negative Metastatic NSCLC without a Targetable Mutation Chalk Talk — Dr Sequist Selecting Patients with Localized NSCLC for Adjuvant Immunotherapy Chalk Talk — Dr Spigel Case: A man in his early 50s with extensive-stage small cell lung cancer (SCLC) — Dr Apuri Case: A man in his mid-60s with extensive-stage SCLC and concurrent prostate cancer — Dr Gandhi CME information and select publications

Featuring perspectives from Drs Jamie Chaft, Solange Peters, Brendan Stiles and Eric Vallieres, including the following topics: Effect of the recent practice-changing data sets in the adjuvant and neoadjuvant treatment of non-small cell lung carcinoma (NSCLC) (0:00) Case: A woman in her late 60s with Stage IIIA squamous cell carcinoma of the lung and a high level of PD-L1 expression (7:46) Strategies to aid shared decision-making in the adjuvant setting for NSCLC (23:43) Potential role of circulating tumor DNA to detect minimal residual disease in the adjuvant and neoadjuvant settings (28:06) Choosing definitive stereotactic radiosurgery versus sublobar resection in patients with NSCLC (34:53) Case: A woman in her early 80s with PD-L1-negative, Stage IIB lung adenocarcinoma with PIK3CA and TP53 mutations and HER2 amplification (37:24) Experiences with surgery after neoadjuvant systemic therapy in NSCLC (55:38) Case: A woman in her mid-70s with localized pulmonary adenocarcinoma with a MET exon 14 skipping mutation (1:06:23) Clinical outcomes from the Phase III CheckMate 816 trial assessing nivolumab in combination with chemotherapy as neoadjuvant therapy for Stage IB-IIIA NSCLC (1:21:36) Case: A 48-year-old man with a 3.1-cm, Stage IB NSCLC with an EGFR exon 19 deletion (1:35:20) Management of oligometastatic disease with surgery and radiation therapy (1:43:32) Numeracy in adjuvant therapy for NSCLC; estimating the benefit to aid patients in therapeutic decision-making (1:49:11) CME information and select publications

In this podcast episode, Jeffrey S. Weber, MD, PhD; Allison Betof Warner, MD, PhD; and Hussein Tawbi, MD, PhD, discuss recent key data on adjuvant and neoadjuvant therapy and review the latest evidence on therapies for metastatic disease.Link to full program:https://bit.ly/3ogPjMoFollow along with the downloadable slideset:https://bit.ly/2XYNIztPresenters:  Jeffrey S. Weber, MD, PhDDeputy DirectorLaura and Isaac Perlmutter Cancer CenterNYU Langone HealthProfessor of MedicineNYU Grossman School of MedicineNew York, New YorkAllison Betof Warner, MD, PhDAssistant MemberAssistant Attending PhysicianMelanoma ServiceDivision of Solid Tumor OncologyDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New YorkHussein Tawbi, MD, PhDProfessorDepartment of Melanoma Medical OncologyThe University of Texas MD Anderson Cancer CenterHouston, Texas 

Featuring perspectives from Drs Arjun Balar, Elisabeth I Heath and Jonathan E Rosenberg on the following topics: Introduction (0:00) Case: A woman in her early 60s with Stage IIIA urothelial bladder cancer (UBC) (4:27) Case: A woman in her late 60s with cisplatin-ineligible muscle-invasive UBC (8:45) Case: A woman in her early 50s with high-grade papillary UBC (14:05) Case: A man in his mid-70s with high-risk non-muscle-invasive UBC (19:44) Non-muscle-invasive bladder cancer; (neo)adjuvant treatment of muscle-invasive bladder cancer (26:50) Case: A man in his early 70s with high-grade UBC and a history of renal transplant (35:47) Case: A man in his late 70s with metastatic transitional cell UBC (41:59) Case: A woman in her late 50s with metastatic UBC and an FGFR3 mutation (46:49 Case: A man in his late 50s with distal urothelial cell carcinoma of the penis (51:33) Metastatic UBC: Checkpoint inhibitors and enfortumab vedotin (57:44) Metastatic UBC: Erdafitinib and other novel agents and strategies (1:07:53) CME information and select publications

Melanoma Update, Issue 1, 2021 — Part 1: Our interview with Dr Davies highlights the following topics as well as cases from his practice: Evolving treatment approaches for regionally metastatic melanoma (0:00) Case: A man in his early 70s with a history of poorly controlled hypertension who is diagnosed with Stage IIIB melanoma with a BRAF V600E mutation (20:42) Case: A woman in her mid-20s with Stage IIIA melanoma with a BRAF V600E mutation (28:46) Case: A man in his early 30s with Stage IIIC melanoma and an NRAS Q61K mutation (37:53) Role of immunotherapy for patients with melanoma in the adjuvant setting (44:16) Adjuvant therapy with BRAF/MEK inhibitors for patients with melanoma and BRAF mutations (48:51) Design and results of the Phase III KEYNOTE-054 trial comparing pembrolizumab to placebo after complete resection of high-risk Stage III melanoma (50:58) Benefits and risks of adjuvant immunotherapy and targeted therapy (53:06) Risk of brain metastases for patients with melanoma; efficacy of nivolumab/ipilimumab in patients with brain metastases (57:16) Activity and tolerability of dabrafenib/trametinib as adjuvant therapy (1:01:38) Emerging data with targeted therapy and immunotherapy in the neoadjuvant setting (1:08:45) Role of immunotherapy and targeted therapy for mucosal and uveal melanoma; improvement in overall survival with the novel bispecific fusion protein tebentafusp for metastatic uveal melanoma (1:13:57) Efficacy of autologous tumor infiltrating lymphocytes (TILs) for patients with metastatic melanoma (1:16:54) Approach to relapse after immunotherapy or targeted therapy in the adjuvant setting (1:19:43) Emerging data from the Phase III CheckMate 915 trial of nivolumab alone or with ipilimumab for patients with resected high-risk melanoma; results of the CheckMate 067 trial of nivolumab or ipilimumab alone or in combination for advanced melanoma (1:23:15) CME information and select publications

Featuring a discussion on recent advances in the treatment of Hodgkin lymphoma with Dr Craig Moskowitz, including the following topics: Hodgkin lymphoma 2020: What are the important questions in up-front therapy? — Craig Moskowitz, MD (00:00) Case: A woman in her early 20s with relapsed/refractory Stage IV classical Hodgkin lymphoma (HL) receives pembrolizumab/gemcitabine/vinorelbine/doxorubicin (21:48) Case: A man in his early 20s with primary refractory Stage IV HL attains a complete response with brentuximab vedotin (BV) and nivolumab (25:04) Case: A woman in her early 30s with newly diagnosed Stage IIIA classical HL is enrolled on the Phase III SWOG-S1826 trial evaluating AVD (doxorubicin/vinblastine/dacarbazine) in combination with BV or nivolumab (30:56) CME information and select publications

Leanne Harling, Doug Mathisen, and Erino Rendina share and debate their approaches to staging, adjuvant therapy, persistent disease, and surgical removal of the primary tumor.

A roundtable discussion with Drs Jason J Luke, Michael A Postow and Ryan J Sullivan on recent developments in the treatment of melanoma, including these topics: Case (Dr Sullivan): A woman in her late teens presents with a nodule on her chin and is diagnosed with Stage IIIA melanoma (00:00) Association between the use of tanning beds and risk of melanoma (02:38) Clinical care of patients with Stage IIIA melanoma (05:21) Risk of recurrence for patients with Stage III melanoma (08:16) Perspective on the benefits and risks of adjuvant therapy for patients with melanoma (09:57) Case (Dr Luke): A man in his early 50s with locally advanced melanoma with a BRAF V600E tumor mutation receives adjuvant dabrafenib and trametinib (15:57) BRAF tumor mutation testing for patients with melanoma (16:56) Therapeutic options in the adjuvant setting for patients with melanoma (18:47) Efficacy and tolerability of immunotherapy in the adjuvant setting (21:51) Choice of dabrafenib/trametinib versus immune checkpoint inhibition as adjuvant therapy for melanoma with BRAF mutation (24:50) Tolerability of and quality of life with BRAF/MEK inhibitor combinations versus immunotherapy (26:48) Monitoring and management of side effects associated with BRAF/MEK inhibitors (30:59) Counseling patients who are receiving BRAF/MEK inhibitors about sun exposure (33:28) Selection of anti-PD-1 antibody therapy for patients with locally advanced melanoma (36:16) Role of vemurafenib in the adjuvant setting (37:26) Case (Dr Postow): A woman in her early 30s with Stage III melanoma with a BRAF V600E tumor mutation receives adjuvant dabrafenib and trametinib (40:33) Reduction in the risk of recurrence with adjuvant therapy for patients with Stage III melanoma (43:29) Recurrence-free survival benefit with adjuvant nivolumab, alone or in combination with ipilimumab, compared to placebo for patients with Stage IV melanoma and no evidence of disease in the Phase II IMMUNED study (45:26) Tumor mutation burden and other potential biomarkers of response to targeted therapy or immune checkpoint inhibition in the adjuvant setting (50:43) Optimal duration of adjuvant therapy with dabrafenib/trametinib and immune checkpoint inhibitor therapy (54:19) Ongoing investigation of neoadjuvant therapy for locally advanced melanoma (58:01) Effect of BRAF/MEK inhibitors on the tumor microenvironment (1:03:28) Challenges with identifying immune-related adverse events (1:06:06) Management of immune-related adverse events in patients receiving immune checkpoint inhibitor therapy (1:07:57) Neurologic toxicities associated with the use of immune checkpoint inhibitors (1:10:42) Multidisciplinary team approach in the management of immune-related adverse events (1:12:45) Educating patients and emergency room personnel about immunotherapy and the potential for immune-related adverse events (1:15:59) Response to immune checkpoint inhibition in noninvasive solid tumors (1:18:34) Incidence and management of nonmelanoma skin cancer (1:20:26) Perspective on the utility of immune checkpoint inhibitors for patients with melanoma who have undergone transplants (1:24:10) Risks and benefits of immunotherapy for patients with metastatic melanoma who have received solid-organ transplants (1:26:30) Monitoring and care of patients with melanoma and preexisting autoimmune disease receiving immune checkpoint inhibitors (1:28:33) Case (Dr Sullivan): A man in his late 50s with Stage IIIC, BRAF wild-type melanoma on his arm experiences intermittent tingling of his mouth during treatment with adjuvant nivolumab (1:33:36) Cranial neuropathy associated with immune checkpoint blockade (1:36:15) Counseling patients about the benefits and risks of immune checkpoint inhibitors in the adjuvant setting (1:38:35) Correlation between toxicity and benefit with immune checkpoint inhibitors (1:42:24) Selection among the BRAF/MEK inhibitor combinations dabrafenib/trametinib, vemurafenib/cobimetinib and encorafenib/binimetinib for patients with metastatic melanoma with BRAF tumor mutations (1:45:46) Advantages of the encorafenib/binimetinib combination for patients with melanoma with BRAF tumor mutations (1:46:42) Use of encorafenib/binimetinib versus dabrafenib/trametinib versus vemurafenib/cobimetinib in clinical practice (1:47:34) COLUMBUS: Results of a Phase III trial comparing encorafenib/binimetinib, vemurafenib and encorafenib for patients with melanoma with BRAF tumor mutations (1:49:08) Case (Dr Luke): A man in his mid-50s with metastatic melanoma with a BRAF V600E tumor mutation experiences a complete resolution of CNS lesions after receiving ipilimumab with nivolumab (1:50:38) Therapeutic approach for patients with melanoma who develop brain metastases (1:52:07) Locoregional versus systemic therapy for patients with brain metastases (1:56:27) Activity and tolerability of nivolumab/ipilimumab in patients with CNS metastases (1:58:58) Management of colitis associated with immune checkpoint inhibitors (2:00:30) Efficacy of radiation therapy for brain metastases in melanoma (2:03:15) Optimal type of radiation therapy for patients with CNS metastases (2:05:39) Radiation necrosis with the combination of stereotactic radiation and immune checkpoint blockade (2:08:02) Case (Dr Postow): A man in his late 60s with low-volume metastatic mucosal melanoma and 1 incidental brain metastasis receives nivolumab/ipilimumab (2:09:39) Response to nivolumab/ipilimumab in patients with brain metastases (2:11:33) Side effects with nivolumab/ipilimumab (2:13:50) Management of hyperthyroidism associated with immunotherapy (2:15:42) Monitoring for endocrinopathy in patients receiving immune checkpoint inhibitors (2:19:03) BRAF tumor mutation status and benefit from nivolumab/ipilimumab (2:21:00) Correlation of PD-L1 expression and benefit from immune checkpoint blockade in patients with BRAF wild-type melanoma (2:23:47) Role of tumor mutation burden and PD-L1 expression as predictive markers of benefit with immune checkpoint blockade (2:26:10) CME information and select publications

Video proceedings from the third in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Dr Edward B Garon, Dr Matthew Gubens, Ms Blanca Ledezma and Ms Wendi S Lee. Introduction (0m0s) Program overview: Dr Love Historical Treatment Paradigms and Related Outcomes for Patients with Stage III Non-Small Cell Lung Cancer (NSCLC); Biologic Rationale for the Evaluation of Immune Checkpoint Inhibitors in This Setting (00:54) Case (Ms Lee): A woman in her early 70s with Stage IIIA adenocarcinoma of the lung who received concurrent chemoradiation therapy and developed Grade 2 esophagitis (1:16) Available Efficacy Data with and Indications for Durvalumab Consolidation in Unresectable Stage III Disease (16:22) Case (Ms Ledezma): A man in his early 70s who received chemoradiation therapy and consolidation durvalumab for new primary Stage III NSCLC after undergoing treatment for Stage IIIB disease 10 years prior (16:34) Case (Ms Lee): A woman in her early 70s with Stage IIIB adenocarcinoma of the lung who underwent concurrent chemoradiation therapy followed by durvalumab consolidation (28:59) Incidence, Recognition and Management of Immune-Mediated and Other Toxicities Associated with the Use of Durvalumab in Unresectable Stage III Disease (55:03) Case (Ms Ledezma): A man in his mid-70s with Stage IIIA NSCLC who enrolled on a clinical trial of neoadjuvant atezolizumab and developed pneumonitis (1:8:31) Case (Ms Ledezma): A woman in her early 50s who was found to have a Stage III adenocarcinoma of the lung with an EGFR tumor mutation while undergoing workup for breast cancer and received chemoradiation therapy and durvalumab consolidation (1:13:58) Case (Ms Lee): A man in his 50s with Stage IIIA adenocarcinoma of the lung who received chemoradiation therapy and consolidation durvalumab after undergoing lobectomy (1:17:10) Select publications

Lung Cancer for Radiation Oncologists — Part 2: Our interview with Dr Langer highlights the following topics and cases from his practice: Case: A woman in her mid-60s, a never smoker, with locally advanced, unresectable adenocarcinoma of the lung and an EGFR exon 18 tumor mutation receives CRT followed by consolidation durvalumab (00:00) Clinical significance and prognostic relevance of microsatellite instability testing in the management of lung cancer (1:29) Risk of recurrence after concurrent CRT for patients with Stage III NSCLC (3:05) Improvement in progression-free and overall survival with the addition of consolidation durvalumab after CRT for patients with Stage III NSCLC on the PACIFIC trial (5:25) Role of immune checkpoint inhibition in the treatment of locally advanced NSCLC with an EGFR tumor mutation (10:15) Perspective on the use of EGFR tyrosine kinase inhibitors in the adjuvant or neoadjuvant setting for patients with locally advanced NSCLC and EGFR tumor mutations (12:50) Initial diagnostic workup and disease management for patients with locally advanced NSCLC (17:17) RTOG-1308: An ongoing Phase III trial of photon versus proton CRT for patients with inoperable Stage II to Stage IIIB NSCLC (19:27) Role of proton beam RT in the treatment of locally advanced NSCLC (21:44) Rationale for the combination of RT and immune checkpoint inhibitors (24:20) Risk of pneumonitis with CRT (26:07) Design and results of the Phase III PACIFIC trial of durvalumab after CRT for unresectable Stage III NSCLC (27:55) Monitoring and management of the toxicities associated with immune checkpoint inhibitors (32:03) Use of durvalumab for patients with preexisting autoimmune disease and for transplant recipients (35:07) Results from the Phase II Hoosier Cancer Research Network LUN14-179 trial of consolidation pembrolizumab after CRT for unresectable Stage III NSCLC (36:45) Ongoing investigation of anti-PD-1/PD-L1 immune checkpoint inhibitors for locally advanced disease (38:56) Case: A man in his mid-80s, a former heavy smoker with multiple comorbidities, is diagnosed with locally advanced squamous cell carcinoma of the lung with a high PD-L1 TPS (tumor proportion score) (40:54) Use of liquid biopsies to detect targetable tumor mutations in patients with lung cancer (44:37) Case: A man in his mid-50s, a former smoker, is diagnosed with Stage IIIA mixed adenosquamous carcinoma of the lung with TTF-1 and p40 tumor mutations (47:17) Perspective on the use of anti-PD-1/PD-L1 antibodies as neoadjuvant therapy for patients with NSCLC (51:22) Case: A man in his early 70s, a current smoker, with adenosquamous carcinoma of the lung and a KRAS mutation receives SBRT (56:28) Optimal approach to RT for patients with locally advanced NSCLC (59:58) Select publications

Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung cancer.

Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung cancer.

Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung cancer.

Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in stage IIIA lung cancer.

Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in stage IIIA lung cancer.

Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in stage IIIA lung cancer.

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the primary treatment options for stage IIIA NSCLC, including chemoradiation and surgery, and discusses trial evidence for each approach.

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the primary treatment options for stage IIIA NSCLC, including chemoradiation and surgery, and discusses trial evidence for each approach.

Dr. Mark Socinski, University of Pittsburgh Medical Center, describes the primary treatment options for stage IIIA NSCLC, including chemoradiation and surgery, and discusses trial evidence for each approach.

Case-based discussion with multiple lung cancer experts on the optimal treatment of a patient with multi-station N2 node-positive squamous cell NSCLC, including whether surgery should be pursued.

Case-based discussion with multiple lung cancer experts on the optimal treatment of a patient with multi-station N2 node-positive squamous cell NSCLC, including whether surgery should be pursued.

Case discussion with Drs. George Blumenschein of MD Anderson Cancer Center and Walter Curran of Emory University, reviewing management options for the range of treatment approaches for patients with stage IIIA N2, locally advanced NSCLC.

Case discussion with Drs. George Blumenschein of MD Anderson Cancer Center and Walter Curran of Emory University, reviewing management options for the range of treatment approaches for patients with stage IIIA N2, locally advanced NSCLC.

ResearchToPractice.com/VPL109 – Case 7: A 62-year-old woman who received adjuvant cisplatin/docetaxel after resection of a Stage IIIA adenocarcinoma of the lung. Interviews conducted by Neil Love, MD. Produced by Research To Practice.

This slide presentation by medical oncologist and lung cancer expert Dr. Jack West covers the most common management strategies for stage IIIA N2 node-positive NSCLC, with a particular focus on a comparison of preoperative treatment followed by surgery vs. chemo and radiation without surgery.

MeetTheProfessors.com – 73-year-old underwent thoracotomy, Stage IIIA left lower lobe adenocarcinoma w/1 pos. mediastinal lymph node; 4 cycles of adj. carbo/pac > adj. radiation therapy, prophylactic cranial irradiation; diagnosed w/metastatic disease